Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma, Kaposi 2HIV Infections 2Acquired Immunodeficiency Syndrome 2

Interventions

Zidovudine 9Doxorubicin 9Vincristine 6Bleomycin 6Interferon alpha-2 5Etoposide 5tecogalan 4Valganciclovir 4Semaxinib 4Liposomes 4Ritonavir 3Paclitaxel 3Nelfinavir 3Filgrastim 3Bevacizumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2sargramostim 2liposomal doxorubicin 2interferon alfa-n1 2Indinavir 2Docetaxel 2Didanosine 2Alitretinoin 2vesnarinone 1valspodar 1tocilizumab 1tin etiopurpurin 1pomalidomide 1pembrolizumab 1halofuginone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Sarcoma, Kaposi × Didanosine × Clear all
NCT00001114 2021-11-01

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
90 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

NCT00000954 2021-10-29

A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 1 Completed
72 enrolled
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡